Cybin
Demonstrates Proof of Concept of its Deuterated Tryptamines for the
Treatment of Depression and Addiction
TORONTO,
CANADA -- April 21, 2021 -- InvestorsHub NewsWire
-- Cybin
Inc. (NEO:CYBN)
(OTCQB:CLXPF)
("Cybin"
or the "Company"),
a biotechnology company focused on progressing psychedelic
therapeutics, today announced that it has successfully
demonstrated Proof
of Concept for its deuterated tryptamine
programs, CYB003 and
CYB004, for
the treatment of depression and addiction.
Multiple
long-acting
psychedelic treatments have been granted
Breakthrough Therapy Designation by the U.S.
Food and Drug Administration ("FDA"). However, these
potential
treatments
produce psychedelic
effects that can last for extended periods of
time, presenting challenges to patient access and
potentially to payer reimbursement. To overcome
these
scalability
issues, Cybin is working to optimize the
duration of action of its treatments
through the
selective deuteration of several short-acting
psychedelic
tryptamines.
"This
Proof-of-Concept data provides strong support for progressing
Cybin's drug development candidates, CYB003 and CYB004, towards
investigational new drug ("IND") filings with the FDA," stated Doug
Drysdale, CEO of Cybin.
An
evaluation
of the
Company's portfolio of psychedelic
tryptamine
molecules
confirms that
selective deuteration retains the full therapeutic
pharmacology across a panel of
serotonin receptors
that is seen with the non-deuterated parent
molecules. This Proof of Concept was
demonstrated using the CEREP 5-HT selectivity panel. Previously published
data
have
confirmed
that
the
principal
effect of
deuteration has led to improved pharmacokinetics consistent with
potential improvement of therapeutic benefit.[1]
Preliminary studies
using an animal model of psychedelic action have also confirmed that
deuteration modifies the pharmacokinetic
profile, while retaining the therapeutic potential of
these psychedelic molecules in the model.
About
Cybin
Cybin is a leading
biotechnology company focused on progressing psychedelic
therapeutics by utilizing proprietary drug discovery platforms,
innovative drug delivery systems, novel formulation approaches and
treatment regimens for psychiatric disorders.
Cautionary
Notes and Forward-Looking Statements
Certain statements
in this news release related to the Company are forward-looking
statements and are prospective in nature. Forward-looking
statements are not based on historical facts, but rather on current
expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied
by the forward-looking statements. These statements generally can
be identified by the use of forward-looking words such as "may",
"should", "could", "intend", "estimate", "plan", "anticipate",
"expect", "believe" or "continue", or the negative thereof or
similar variations. Forward-looking statements in this news
release may include statements regarding
enhanced liquidity, the value of additional capital markets
exposure, access to institutional and retail investors, the
Company's new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders.
There are numerous risks and uncertainties that could cause actual
results and Cybin's plans and objectives to differ materially from
those expressed in the forward-looking information. Actual results
and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
Cybin makes no
medical, treatment or health benefit claims about Cybin's proposed
products. The U.S. Food and Drug Administration, Health Canada or
other similar regulatory authorities have not evaluated claims
regarding psilocybin, psychedelic tryptamine, tryptamine
derivatives or other psychedelic compounds or nutraceutical
products. The efficacy of such products has not been confirmed by approved
research. There is no assurance that the use of psilocybin,
psychedelic tryptamine, tryptamine derivatives or other psychedelic
compounds or nutraceuticals can diagnose, treat, cure or prevent
any disease or condition. Vigorous scientific research and clinical
trials are needed. Cybin has not conducted clinical trials for the
use of its proposed products. Any references to quality,
consistency, efficacy and safety of potential products do not imply
that Cybin verified such in clinical trials or that Cybin will
complete such trials. If Cybin cannot obtain the approvals or
research necessary to commercialize its business, it may have a
material adverse effect on Cybin's performance and
operations.
The NEO
Exchange has neither approved nor disapproved the contents of this
news release and is not responsible for the adequacy and accuracy
of the contents herein.
Investor
Contacts:
Tim Regan/Scott
Eckstein
KCSA Strategic
Communications
Cybin@kcsa.com
Lisa M.
Wilson
In-Site
Communications, Inc.
lwilson@insitecony.com
Media
Contacts:
John
Kanakis
Cybin
Inc.
John@cybin.com
Annie
Graf
KCSA Strategic
Communications
agraf@kcsa.com
Faith
Pomeroy-Ward
In-Site
Communications, Inc.
Faith@insitecony.com